Skip to main content

Table 6 The correlation between CSC marker levels in sera with clinicopathological features and laboratory results in early stage CCA patients

From: Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma

VariablesEarly stage (TNM stage I, II)
nCD44pCD44v6pCD44v8-10pEpCAMp
Sex
 Female220.47 ± 0.13 0.80 ± 0.17 0.70 ± 0.13 0.46 ± 0.16 
 Male380.51 ± 0.160.3060.79 ± 0.180.8610.70 ± 0.150.9130.48 ± 0.150.623
Age (year)
 Less than 61300.51 ± 0.15 0.82 ± 0.15 0.72 ± 0.12 0.50 ± 0.15 
 61 or greater300.49 ± 0.160.5790.77 ± 0.200.2200.68 ± 0.170.2760.44 ± 0.160.102
Tumor site
 Intrahepatic310.50 ± 0.13 0.80 ± 0.15 0.71 ± 0.13 0.47 ± 0.13 
 Extrahepatic290.49 ± 0.180.8880.79 ± 0.200.7780.70 ± 0.170.7100.47 ± 0.180.928
Histology type
 Papillary380.52 ± 0.13 0.82 ± 0.14 0.72 ± 0.13 0.48 ± 0.16 
 Others220.47 ± 0.180.2290.74 ± 0.210.0790.68 ± 0.170.2770.45 ± 0.160.449
Tumor marker
 CA19-9 (U/mL)         
  < 37240.44 ± 0.13 0.77 ± 0.16 0.67 ± 0.14 0.40 ± 0.11 
  ≥ 37210.57 ± 0.150.0060.85 ± 0.130.0720.77 ± 0.100.0110.54 ± 0.14< 0.001
 CEA (ng/mL)
  < 2.5160.48 ± 0.12 0.81 ± 0.15 0.70 ± 0.14 0.44 ± 0.12 
  ≥ 2.5300.52 ± 0.160.4050.81 ± 0.150.9370.72 ± 0.130.6530.48 ± 0.150.286
 AFP (IU/mL)
  < 5330.48 ± 0.15 0.79 ± 0.14 0.70 ± 0.13 0.45 ± 0.14 
  ≥ 540.55 ± 0.210.3870.80 ± 0.140.8940.71 ± 0.130.9370.50 ± 0.210.553
Liver function test
 Direct bilirubin (mg/dL)
  < 1.5350.48 ± 0.14 0.79 ± 0.15 0.69 ± 0.13 0.44 ± 0.13 
  ≥ 1.5180.53 ± 0.190.2610.79 ± 0.220.9370.71 ± 0.180.6000.49 ± 0.170.276
 Total bilirubin (mg/dL)
  < 2.5330.49 ± 0.14 0.80 ± 0.15 0.70 ± 0.14 0.46 ± 0.13 
  ≥ 2.5220.51 ± 0.180.5710.78 ± 0.210.6960.70 ± 0.170.8660.46 ± 0.170.992
 ALT (U/L)
  < 40300.50 ± 0.14 0.81 ± 0.16 0.73 ± 0.12 0.46 ± 0.11 
  ≥ 40230.48 ± 0.180.5210.75 ± 0.190.2380.66 ± 0.170.0890.46 ± 0.190.888
 AST (U/L)
  < 40280.48 ± 0.13 0.79 ± 0.16 0.70 ± 0.13 0.47 ± 0.13 
  ≥ 40250.50 ± 0.180.7090.78 ± 0.190.7940.69 ± 0.170.7520.46 ± 0.170.834
 ALP (U/L)
  < 130180.45 ± 0.15 0.76 ± 0.16 0.68 ± 0.13 0.42 ± 0.12 
  ≥ 130350.52 ± 0.160.1290.80 ± 0.180.4790.71 ± 0.160.5750.48 ± 0.160.151
  1. CD44 cluster of differentiation 44, CD44v CD44 variant, EpCAM epithelial cell adhesion molecules, TNM primary tumor-node-metastasis, CA19-9 cancer antigen 19-9, CEA carcinoembryonic antigen, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase